Odomzo (sonidegib) — United Healthcare
Diffuse basal cell carcinoma formation (e.g., Gorlin syndrome, other genetic forms of multiple BCC)
Initial criteria
- Patient is less than 19 years of age OR
- Diagnosis of nodal metastatic basal cell carcinoma OR
- Diagnosis of diffuse basal cell carcinoma formation (e.g., Gorlin syndrome, other genetic forms of multiple BCC) OR
- Diagnosis of locally advanced basal cell carcinoma AND one of the following: cancer has recurred following surgery; cancer has recurred following radiation; patient is not a candidate for surgery; patient is not a candidate for radiation
- Drug is recognized for treatment of the cancer indication by the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Odomzo therapy
Approval duration
12 months